TRACON Pharmaceuticals, Inc. Common Stock
TCON
TCON was delisted on the 27th of June, 2024.
26 hedge funds and large institutions have $29.4M invested in TRACON Pharmaceuticals, Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 5 closing their positions.
864% more capital invested
Capital invested by funds: $3.05M → $29.4M (+$26.3M)
160% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 5
44% more funds holding
Funds holding: 18 → 26 (+8)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$5.79M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$5.39M |
| 3 |
BFM
Boothbay Fund Management
New York
|
+$633K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$219K |
| 5 |
Jane Street
New York
|
+$104K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$525K |
| 2 |
TI
Telemetry Investments
New York
|
-$189K |
| 3 |
Two Sigma Investments
New York
|
-$174K |
| 4 |
Two Sigma Advisers
New York
|
-$109K |
| 5 |
WS
Wedbush Securities
Los Angeles,
California
|
-$50K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Millennium Management
New York
| $358 | -$7.01K | -131 | -4% |
|
|
27
Two Sigma Investments
New York
| – | -$174K | -4,436 | Closed |
|
|
28
Two Sigma Advisers
New York
| – | -$109K | -2,770 | Closed |
|
|
WS
29
Wedbush Securities
Los Angeles,
California
| – | -$50K | -1,285 | Closed |
|
30
Citadel Advisors
Miami,
Florida
| – | -$49K | -1,238 | Closed |
|
31
Morgan Stanley
New York
| – | -$2K | -56 | Closed |
|
TCON Hedge Fund Activity: Q3 2020 in Review
26 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in TRACON Pharmaceuticals, Inc. Common Stock (TCON) for Q3 2020, worth a combined $29.4M — up 864% from $3.05M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new TCON positions and 5 closed out — a net gain of 8 holders — while 3 added to existing stakes and 4 trimmed.
The largest buyer was Ikarian Capital, opening a new position worth an estimated $5.79M. The largest seller was Renaissance Technologies, cutting an estimated $525K.
- 26 institutional investors held TRACON Pharmaceuticals, Inc. Common Stock (TCON) as of Q3 2020, up from 18 in Q2 2020.
- Funds reported $29.4M of TRACON Pharmaceuticals, Inc. Common Stock stock for Q3 2020, up 864% quarter-over-quarter.
- 13 funds opened new TRACON Pharmaceuticals, Inc. Common Stock positions in Q3 2020 and 5 closed out, a net change of +8 holders.
- The largest TRACON Pharmaceuticals, Inc. Common Stock buyer in Q3 2020 was Ikarian Capital, an estimated $5.79M added.
- The largest TRACON Pharmaceuticals, Inc. Common Stock seller in Q3 2020 was Renaissance Technologies, an estimated $525K sold.
Based on aggregated 13F filings for Q3 2020.